Drug Manufacturers - Specialty & Generic
Compare Stocks
2 / 10Stock Comparison
YCBD vs CGC
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
YCBD vs CGC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $9M | $124M |
| Revenue (TTM) | $19M | $294M |
| Net Income (TTM) | $-328M | $-327M |
| Gross Margin | 59.8% | 22.8% |
| Operating Margin | -5.7% | -24.1% |
| Total Debt | $778M | $348M |
| Cash & Equiv. | $2M | $114M |
YCBD vs CGC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| cbdMD, Inc. (YCBD) | 100 | 0.2 | -99.8% |
| Canopy Growth Corpo… (CGC) | 100 | 0.7 | -99.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: YCBD vs CGC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
YCBD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.66
- Rev growth -1.5%, EPS growth 39.1%, 3Y rev CAGR -18.5%
- Lower volatility, beta 0.66, current ratio 2.05x
CGC is the clearest fit if your priority is long-term compounding.
- -94.2% 10Y total return vs YCBD's -100.0%
- -10.2% vs YCBD's -10.5%
- -29.5% ROA vs YCBD's -27.8%, ROIC -10.2% vs -0.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -1.5% revenue growth vs CGC's -9.5% | |
| Quality / Margins | -6.5% margin vs CGC's -111.0% | |
| Stability / Safety | Beta 0.66 vs CGC's 1.90 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -10.2% vs YCBD's -10.5% | |
| Efficiency (ROA) | -29.5% ROA vs YCBD's -27.8%, ROIC -10.2% vs -0.4% |
YCBD vs CGC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
YCBD vs CGC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
YCBD leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CGC is the larger business by revenue, generating $294M annually — 15.7x YCBD's $19M. YCBD is the more profitable business, keeping -6.5% of every revenue dollar as net income compared to CGC's -111.0%. On growth, YCBD holds the edge at +980.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $19M | $294M |
| EBITDAEarnings before interest/tax | -$286M | -$32M |
| Net IncomeAfter-tax profit | -$328M | -$327M |
| Free Cash FlowCash after capex | -$853M | -$86M |
| Gross MarginGross profit ÷ Revenue | +59.8% | +22.8% |
| Operating MarginEBIT ÷ Revenue | -5.7% | -24.1% |
| Net MarginNet income ÷ Revenue | -6.5% | -111.0% |
| FCF MarginFCF ÷ Revenue | -16.9% | -29.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +980.1% | +20.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +83.6% | +83.8% |
Valuation Metrics
YCBD leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $9M | $124M |
| Enterprise ValueMkt cap + debt − cash | $785M | $296M |
| Trailing P/EPrice ÷ TTM EPS | -0.84x | -0.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.48x | 0.62x |
| Price / BookPrice ÷ Book value/share | 0.51x | 0.34x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
CGC leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
YCBD delivers a -3.6% return on equity — every $100 of shareholder capital generates $-4 in annual profit, vs $-43 for CGC. CGC carries lower financial leverage with a 0.72x debt-to-equity ratio, signaling a more conservative balance sheet compared to YCBD's 107.70x.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -3.6% | -43.1% |
| ROA (TTM)Return on assets | -27.8% | -29.5% |
| ROICReturn on invested capital | -0.4% | -10.2% |
| ROCEReturn on capital employed | -47.1% | -12.4% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 107.70x | 0.72x |
| Net DebtTotal debt minus cash | $776M | $235M |
| Cash & Equiv.Liquid assets | $2M | $114M |
| Total DebtShort + long-term debt | $778M | $348M |
| Interest CoverageEBIT ÷ Interest expense | — | -7.79x |
Total Returns (Dividends Reinvested)
CGC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CGC five years ago would be worth $47 today (with dividends reinvested), compared to $7 for YCBD. Over the past 12 months, CGC leads with a -10.2% total return vs YCBD's -10.5%. The 3-year compound annual growth rate (CAGR) favors CGC at -55.7% vs YCBD's -61.8% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -21.3% | -3.4% |
| 1-Year ReturnPast 12 months | -10.5% | -10.2% |
| 3-Year ReturnCumulative with dividends | -94.4% | -91.3% |
| 5-Year ReturnCumulative with dividends | -99.9% | -99.5% |
| 10-Year ReturnCumulative with dividends | -100.0% | -94.2% |
| CAGR (3Y)Annualised 3-year return | -61.8% | -55.7% |
Risk & Volatility
Evenly matched — YCBD and CGC each lead in 1 of 2 comparable metrics.
Risk & Volatility
YCBD is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than CGC's 1.90 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CGC currently trades 48.3% from its 52-week high vs YCBD's 35.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.66x | 1.90x |
| 52-Week HighHighest price in past year | $2.56 | $2.38 |
| 52-Week LowLowest price in past year | $0.47 | $0.84 |
| % of 52W HighCurrent price vs 52-week peak | +35.6% | +48.3% |
| RSI (14)Momentum oscillator 0–100 | 51.9 | 48.3 |
| Avg Volume (50D)Average daily shares traded | 1.7M | 10.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $14.47 |
| # AnalystsCovering analysts | — | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
YCBD leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). CGC leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
YCBD vs CGC: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is YCBD or CGC a better buy right now?
For growth investors, cbdMD, Inc.
(YCBD) is the stronger pick with -1. 5% revenue growth year-over-year, versus -9. 5% for Canopy Growth Corporation (CGC). Analysts rate Canopy Growth Corporation (CGC) a "Hold" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — YCBD or CGC?
Over the past 5 years, Canopy Growth Corporation (CGC) delivered a total return of -99.
5%, compared to -99. 9% for cbdMD, Inc. (YCBD). Over 10 years, the gap is even starker: CGC returned -94. 2% versus YCBD's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — YCBD or CGC?
By beta (market sensitivity over 5 years), cbdMD, Inc.
(YCBD) is the lower-risk stock at 0. 66β versus Canopy Growth Corporation's 1. 90β — meaning CGC is approximately 187% more volatile than YCBD relative to the S&P 500. On balance sheet safety, Canopy Growth Corporation (CGC) carries a lower debt/equity ratio of 72% versus 108% for cbdMD, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — YCBD or CGC?
By revenue growth (latest reported year), cbdMD, Inc.
(YCBD) is pulling ahead at -1. 5% versus -9. 5% for Canopy Growth Corporation (CGC). On earnings-per-share growth, the picture is similar: cbdMD, Inc. grew EPS 39. 1% year-over-year, compared to 37. 1% for Canopy Growth Corporation. Over a 3-year CAGR, CGC leads at -17. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — YCBD or CGC?
cbdMD, Inc.
(YCBD) is the more profitable company, earning -10. 6% net margin versus -222. 4% for Canopy Growth Corporation — meaning it keeps -10. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: YCBD leads at -11. 3% versus -43. 5% for CGC. At the gross margin level — before operating expenses — YCBD leads at 56. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — YCBD or CGC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is YCBD or CGC better for a retirement portfolio?
For long-horizon retirement investors, cbdMD, Inc.
(YCBD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66)). Canopy Growth Corporation (CGC) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (YCBD: -100. 0%, CGC: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between YCBD and CGC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.